Zhuang Wu

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.

W. Feng, Xiaoqing Liu, Yunpeng Liu, 2019, The Lancet. Respiratory medicine.

TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib.

X. Yi, Jian-ping Lu, Y. Guan, 2018, Journal of thoracic disease.

Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review

Gang Chen, M. Fang, You‐cai Zhu, 2017, Thoracic cancer.

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study

W. Feng, K. Ma, G. Selvaggi, 2024, Cancer communications.

Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study

Dong Wang, M. Fang, T. Lv, 2020, Translational lung cancer research.